This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
DHX9 / ATP-dependent RNA helicase A · IHC design guide
Design Immunohistochemistry for DHX9
Plan DHX9 paraffin-section IHC around broadly nuclear tissue staining (HPA tissue IHC). Start the IHC-validated antibody at 0.5–1 μg/mL (datasheet A02550-1), then assess nuclear staining across cell types.
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
DHX9 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Predominantly nuclear in tissue (HPA tissue IHC) | |
| Staining pattern | Nuclear staining across many tissue cell types (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A02550-1) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Nucleocytoplasmic shuttling may add cytoplasmic signal (UniProt) | |
| Regulation | Low tissue specificity (HPA tissue RNA) | |
| Isoform / epitope | 2 isoforms; antibody epitope coverage is unknown (UniProt) |
Section 1
Recommended DHX9 IHC & IF Protocols
The catalog antibody has a datasheet IHC-P protocol (datasheet A02550-1). The published options below cover hepatocellular carcinoma tissue microarrays and mouse paraffin sections (PMC11816161; PMC8649379; PMC5023453).
| Sample | Paraffin-embedded human gastric cancer tissue; fixative not specified (datasheet A02550-1) |
| Fixation | Image fixative and duration unreported (datasheet A02550-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A02550-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A02550-1) |
| Primary antibody | Rabbit anti-DHX9, 0.5-1μg/ml (datasheet A02550-1) |
| Primary incubation | Overnight at 4 °C (datasheet A02550-1) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A02550-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | DHX9-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Ubiquitous nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA pH 8.0 retrieval for the catalog antibody (datasheet A02550-1). Use each paper’s stated retrieval when reproducing its protocol (PMC8649379; PMC5023453).
Section 2
What Is the Expected DHX9 Staining Pattern?
DHX9 should appear predominantly in nuclei across many cell types in paraffin tissue sections (HPA tissue IHC: ubiquitous nuclear expression; Supported reliability). Strong staining is documented in adrenal, appendix, breast and cervical glandular cells, bone marrow hematopoietic cells, and selected brain cells (HPA tissue IHC: High). A membrane rim is not expected for this protein (UniProt Q08211: no transmembrane segment).
| Crisp nuclear chromogen in the expected cells, with little signal over empty spaces or tissue edges. | This fits the reported ubiquitous nuclear tissue pattern; compare intensity within the same section, since HPA lists High staining in selected cell populations rather than a universal intensity threshold (HPA tissue IHC: ubiquitous nuclear expression; High in listed cells). |
| Signal is predominantly cytoplasmic, membranous or extracellular, while nuclei remain pale. | Check for a staining artefact or nonspecific binding before calling this DHX9: HPA tissue IHC reports a nuclear pattern (HPA tissue IHC: ubiquitous nuclear expression). Cytoplasmic DHX9 is biologically possible, so cytoplasmic signal alone does not prove an artefact (UniProt Q08211: cytoplasmic localization and nucleocytoplasmic shuttling). |
| Strong colour marks a cell population other than the one expected to stain strongly in a selected tissue. | Review morphology and cell identity first. HPA identifies High staining in specified populations, but its ubiquitous nuclear profile does not make neighboring cells true negatives (HPA tissue IHC: High in listed cells; ubiquitous nuclear expression). A mismatch concentrated over debris, vessels or cell borders warrants checks for cross-reactivity or endogenous detection activity (general IHC practice). |
| A diffuse haze covers nuclei, cytoplasm and cell-free areas, obscuring cell boundaries. | Do not score the haze as DHX9 expression: it prevents assessment of the nuclear pattern reported by HPA (HPA tissue IHC: ubiquitous nuclear expression). Inspect a reagent control and adjust blocking, washes or chromogen development according to the detection system (general IHC practice). |
| No convincing nuclear colour appears in a well-preserved, documented High-staining cell population. | Treat the result as an unresolved assay failure before interpreting the sample as DHX9-negative (HPA tissue IHC: High in listed cells). Check that nuclei are identifiable with counterstain, then verify the primary antibody, detection reagents and a parallel positive section (general IHC practice). |
💡Expected DHX9 appearanceCall the stain positive when intact cells show clearly localized nuclear chromogen, with strong staining in the selected HPA High populations (HPA tissue IHC: ubiquitous nuclear expression; High in listed cells); broad extracellular haze or a membrane-only outline is suspicious (general IHC practice; UniProt Q08211: no transmembrane segment).
| Which tissue and cells provide an interpretable positive comparison? | Use a documented High population, such as appendix glandular cells or bone marrow hematopoietic cells, and identify that population morphologically (HPA tissue IHC: High). HPA lists no negative tissue in this payload; an unstained unrelated cell population is not an established DHX9-negative control (HPA tissue IHC: negative list empty; ubiquitous nuclear expression). |
| How strongly is the tissue pattern validated? | The tissue profile is Supported because antibody staining is highly consistent with RNA expression (HPA tissue IHC: reliability Supported). HPA028050 and CAB011819 have Supported IHC status; HPA055684 has no IHC status in the supplied list (HPA antibodies: IHC statuses). These labels support pattern comparison, not an exact intensity cutoff. |
| What does protein location predict? | Expect nuclear staining in routine tissue assessment, while allowing biologically plausible nucleolar or cytoplasmic signal in context (HPA tissue IHC: ubiquitous nuclear expression; UniProt Q08211: nucleus, nucleolus and cytoplasm). Do not infer that every cytoplasmic deposit is specific from localization alone (general IHC practice). |
| Do protein topology or processing predict a surface pattern? | A surface-only outline has no support from the supplied topology: DHX9 has no transmembrane segment or signal peptide, and its annotated chain spans residues 1–1270 (UniProt Q08211: topology and processing). These annotations do not establish how fixation or antigen retrieval affects this antibody. |
| What should IF/ICC show? | Predominant nucleoplasmic fluorescence, with additional nucleolar staining, matches the cell-image profile (HPA subcellular ICC-IF: nucleoplasm enhanced; nucleoli supported). HPA lists images from A-431, U-251MG and U2OS; these observations inform localization but do not supply an IF/ICC protocol here (HPA subcellular ICC-IF: imaged cell lines). |
| Can the supplied evidence specify antigen retrieval? | No retrieval condition or target-specific fixation sensitivity is supplied by UniProt or HPA. If nuclear signal is weak, compare retrieval conditions with matched positive sections while keeping other variables stable (general IHC practice); do not interpret the HPA High label as evidence for a particular retrieval treatment. |
| Situation | Likely cause | Next action |
|---|---|---|
| Nuclei are blank in both the study section and a documented High population. | The run may have failed at primary incubation, retrieval or detection; the HPA High label alone cannot identify the failed step (HPA tissue IHC: High in listed cells; general IHC practice). | Confirm section integrity and counterstain, reagent order, antibody suitability for IHC and detection performance on a parallel positive section (general IHC practice). |
| Nuclear signal is present but too faint to score confidently. | A weak run may reflect assay conditions or low signal in that population; HPA does not assign the same intensity to every cell (HPA tissue IHC: High in listed cells; ubiquitous nuclear expression). | Compare with a documented High cell population; optimize retrieval or primary-antibody concentration with matched sections, using the antibody's actual IHC instructions when available (general IHC practice). |
| Colour is mainly cytoplasmic or outlines cell membranes. | This departs from the HPA tissue pattern, although UniProt also records cytoplasmic localization; membrane localization lacks support from topology (HPA tissue IHC: ubiquitous nuclear expression; UniProt Q08211: cytoplasm, no transmembrane segment). | Check nuclear counterstain and morphology, then compare a positive section and reagent control before assigning the signal to DHX9 (general IHC practice). |
| Diffuse colour persists outside cells or across the whole section. | Background from binding or detection can hide the expected nuclear pattern (general IHC practice; HPA tissue IHC: ubiquitous nuclear expression). | Inspect a control lacking primary antibody; improve blocking or washing and reduce excessive chromogen development as indicated by the control (general IHC practice). |
| An unexpected cell population dominates the stain. | Cell misidentification, cross-reactivity or endogenous detection activity are possible; ubiquitous nuclear expression means adjacent cells cannot automatically serve as negative references (general IHC practice; HPA tissue IHC: ubiquitous nuclear expression). | Recheck morphology against the HPA High population, then examine a reagent control and a separately validated IHC antibody if available (HPA tissue IHC: High; HPA antibodies: Supported IHC for HPA028050 and CAB011819). |
| Only part of a section stains, or edge staining exceeds the center. | Uneven reagent coverage or section handling may create a spatial gradient unrelated to the reported cell pattern (general IHC practice; HPA tissue IHC: ubiquitous nuclear expression). | Check section adhesion, full reagent coverage and incubation consistency; repeat with a parallel documented High section before comparing biological intensity (general IHC practice; HPA tissue IHC: High in listed cells). |
Experiment evidence
IHC & IF images showing DHX9 staining
A02550-1 · IHCIHC analysis of DHX9 using anti-DHX9 antibody (A02550-1). DHX9 was detected in paraffin-embedded section of human gastric cancer tissue. Hea
A02550-1 · IHCIHC analysis of DHX9 using anti-DHX9 antibody (A02550-1). DHX9 was detected in paraffin-embedded section of human lung cancer tissue. Heat m
A02550-1 · IFIF analysis of DHX9 using anti-DHX9 antibody (A02550-1). DHX9 was detected in immunocytochemical section of U20S cells. Enzyme antigen retri
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000135829-DHX9/tissue/cerebral+cortex#imid_7057488
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000135829-DHX9/tissue/colon#imid_7057414
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000135829-DHX9/tissue/liver#imid_7057431
HPA · PancreasHuman Protein Atlas IHC, Pancreas. Source: https://www.proteinatlas.org/ENSG00000135829-DHX9/tissue/pancreas#imid_7057382
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB011819; green = DHX9, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB011819; green = DHX9, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for DHX9 IHC & IF
🧪Run bone marrow first: hematopoietic cells should stain, with predominantly nuclear signal (HPA: High in hematopoietic cells; UniProt Q08211: nuclear localization). HPA detects DHX9 in all 45 scored tissues, so there is no HPA negative tissue; no-primary and isotype controls carry the negative comparison, while any cells lacking visible signal on the positive slide can indicate local background but are not validated negative cells (HPA: no negative tissue rows; detected in all 45 scored tissues).
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: None in HPA: DHX9 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show DHX9 in A-431, U-251MG, U2OS, with annotated localisation: Nucleoplasm (enhanced) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only section and a concentration-matched rabbit IgG isotype control for the captioned rabbit primary, plus DHX9 knockout material as a biological negative if available (caption: rabbit anti-DHX9; standard IHC controls). For bone marrow, block endogenous peroxidase and check background before interpreting DAB staining in hematopoietic cells (HPA: bone marrow hematopoietic cells High; standard chromogenic IHC practice).
⚠️Feasibility: The selected A02550-1 paraffin-section caption does not state a fixative, and no target-specific fixation window or fixation effect is reported in the supplied evidence (A02550-1 caption: fixative unreported). The caption uses heat retrieval in EDTA at pH 8.0, but does not establish whether retrieval is required; no supplied comparison establishes that frozen sections or IF/ICC are easier (A02550-1 caption: EDTA pH 8.0 heat retrieval). Bone marrow can produce endogenous peroxidase background with DAB, so assess it with the no-primary control (HPA: bone marrow hematopoietic cells High; standard chromogenic IHC practice).
HPA tissue IHC evidence for DHX9
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Caudate | Glial cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: DHX9 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced DHX9 IHC Tips
Troubleshoot DHX9 staining in paraffin sections by checking retrieval, nuclear localisation, controls, and scoring before interpreting cytoplasmic signal.
How should I retrieve DHX9 in paraffin sections when nuclear staining is weak?
Start with heat-mediated retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A02550-1). The catalog antibody detected DHX9 in a paraffin section of human gastric cancer after this retrieval, at 1 μg/ml overnight at 4°C (datasheet A02550-1). If staining remains weak, compare retrieval duration or a different buffer on matched sections while holding antibody concentration and detection constant (standard IHC practice). Check whether nuclei stain in an expected positive area before increasing detection intensity; DHX9 has a ubiquitous nuclear tissue profile (HPA tissue IHC). Record the retrieval conditions for every comparison (standard IHC practice).
Could fixation explain weak or uneven DHX9 staining?
Target-specific fixation sensitivity is unknown because the selected tissue-IHC caption does not state a fixative (datasheet A02550-1). Do not treat its paraffin-section result as evidence that a particular fixation method preserves the DHX9 epitope (datasheet A02550-1). Compare sections with documented processing histories under the same EDTA pH 8.0 retrieval and 1 μg/ml primary-antibody conditions (datasheet A02550-1; standard IHC practice). If signal differs, check nuclear morphology, section integrity, and within-run controls before assigning the difference to fixation (standard IHC practice). Record the fixative and processing history alongside the staining result so the comparison can be repeated (standard IHC practice).
Should DHX9 stain only nuclei in chromogenic IHC?
Use nuclear staining as the main tissue-IHC expectation: DHX9 has ubiquitous nuclear expression, while cell imaging places it mainly in the nucleoplasm and additionally in nucleoli (HPA tissue IHC; HPA subcellular). DHX9 can also shuttle and occur in cytoplasmic ribonucleoprotein granules, so cytoplasmic signal requires context rather than automatic rejection (UniProt Q08211 subcellular). Compare cytoplasmic staining with nuclear staining in the same well-preserved cells and examine whether it follows cell boundaries or damaged tissue (standard IHC practice). For discrete foci, assess their location against a nuclear counterstain before assigning a compartment (standard IHC practice). Report nuclear and cytoplasmic patterns separately (standard IHC practice).
How do I assess an unexpected DHX9 staining pattern when the antibody epitope is unspecified?
DHX9 has 2 annotated isoforms and domains including N-terminal RNA-binding regions and a helicase core (UniProt Q08211 isoforms; UniProt Q08211 domains). Its record also lists modified residues, but the supplied catalog caption gives no epitope coordinates or isoform selectivity (UniProt Q08211 modified residues; datasheet A02550-1). Therefore, an altered nuclear pattern alone cannot identify an isoform or a modification-dependent epitope (UniProt Q08211 isoforms; standard IHC interpretation). Check the antibody's documented immunogen or epitope before making those assignments, and compare staining with an independently validated reagent if available (standard IHC practice). Keep retrieval and detection conditions matched when comparing reagents (standard IHC practice).
How can I investigate DHX9 localisation by IF without overinterpreting the IHC result?
For IF or ICC, use a nuclear counterstain to distinguish nucleoplasmic from nucleolar signal; these are the reported main and additional DHX9 locations (HPA subcellular; standard IF practice). Multiplex with a validated marker for the cell type under study, then confirm that both channels identify the same intact cells (standard IF practice). Choose fluorophores and controls after inspecting tissue autofluorescence in each channel (standard IF practice). Because DHX9 has no transmembrane segment and occupies intracellular compartments, use permeabilisation appropriate for access to nuclear and any cytoplasmic epitopes (UniProt Q08211 topology; UniProt Q08211 subcellular; standard IF practice). Optimise IF conditions independently; the selected caption documents chromogenic tissue IHC (datasheet A02550-1).
What should I check when DHX9 DAB staining obscures nuclei?
The catalog tissue-IHC example used a 10% goat-serum block, 1 μg/ml primary antibody overnight at 4°C, and a biotinylated secondary for 30 minutes at 37°C (datasheet A02550-1). If DAB obscures nuclei, inspect a no-primary control and reduce excessive chromogen development before changing the retrieval condition (standard IHC practice). Apply a peroxidase block and assess endogenous biotin background when using a biotin-based detection system (standard IHC practice; datasheet A02550-1 detection). Check section edges, folds, and damaged areas separately from intact tissue (standard IHC practice). Judge specific signal against nuclear morphology and the no-primary control (HPA tissue IHC; standard IHC practice).
How should I score DHX9 staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and a nuclear positivity threshold from controls before scoring; DHX9 shows ubiquitous nuclear tissue expression (HPA tissue IHC; standard IHC practice). For intensity-based analysis, calculate a nuclear H-score from the percentage of cells at each staining intensity, or report the percentage of positive nuclei (standard IHC practice). For spatial questions, report positive-cell density per mm² of viable, analysable tissue (standard IHC practice). Normalise counts to the number of eligible nuclei or sampled viable area, and exclude folds, necrosis, and section edges using the same rules across slides (standard IHC practice). Score cytoplasmic signal separately if it is part of the study question (UniProt Q08211 subcellular; standard IHC practice).
When is apparent DHX9 positivity more likely to be artefact?
A convincing result includes staining in intact nuclei, consistent with DHX9's ubiquitous nuclear tissue profile and predominantly nucleoplasmic location (HPA tissue IHC; HPA subcellular). Treat signal confined to tissue edges, folds, or necrotic areas as suspect until it persists in well-preserved regions (standard IHC practice). Diffuse cytoplasmic staining without corresponding nuclear signal deserves a control review, although DHX9 can shuttle and enter cytoplasmic granules (UniProt Q08211 subcellular; standard IHC practice). Compare a no-primary section and the peroxidase block to identify detection background or endogenous enzyme activity (standard IHC practice). Confirm that the stained cells match the population being scored before making a biological claim (standard IHC practice).
Boster reagents
Best DHX9 / ATP-dependent RNA helicase A IHC Antibodies
A02550-1 has IHC images from human gastric and lung cancer paraffin sections and IF images from human gastric cancer sections and U20S cells (catalog image captions).
Real IHC data
Anti-RNA Helicase A/DHX9 Antibody ®
Cat # A02550-1
A02550-1 is the only SKU with a rendering card; its IHC images show human gastric and lung cancer paraffin sections (catalog IHC image captions). Its IF images show human gastric cancer paraffin sections and U20S cells (catalog IF image captions).
Which to pick: Choose A02550-1 for tissue IHC: its own captions document paraffin sections, EDTA retrieval at pH 8.0, and 1 μg/ml primary antibody; the fixative is unreported (A02550-1 IHC image captions). For IF/ICC, A02550-1 has image evidence at 2 μg/ml in human gastric cancer sections and U20S cells, while M02550 lists IF/ICC without an image caption (catalog IF image captions; M02550 applications and image fields). Both list human, mouse, and rat reactivity, but the documented IHC images are human only; M02550 is monoclonal, while A02550-1 is polyclonal (catalog reactivity, clone, description, and IHC image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q08211 (DHX9_HUMAN, ATP-dependent RNA helicase A).
- Human Protein Atlas. DHX9 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. DHX9 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the nucleoli..
- Human Protein Atlas. DHX9 antibody validation summary (3 antibodies).
- Targeting Hepatocellular Carcinoma Growth: Haprolid's Inhibition of AKT Signaling Through DExH-Box Helicase 9 Downregulation. Cancers 2025 — PMC11816161.
- High expression of DHX9 promotes the growth and metastasis of hepatocellular carcinoma. Journal of clinical laboratory analysis 2021 — PMC8649379.
- High Levels of DEAH-Box Helicases Relate to Poor Prognosis and Reduction of DHX9 Improves Radiosensitivity of Hepatocellular Carcinoma. Frontiers in oncology 2022 — PMC9256992.
- Tumor cell survival dependence on the DHX9 DExH-box helicase. Oncogene 2016 — PMC5023453.
- PubMed PMID:8344961 — UniProt-cited evidence.
- PubMed PMID:8690889 — UniProt-cited evidence.
- PubMed PMID:9111062 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for DHX9 (ATP-dependent RNA helicase A). Expected localisation Predominantly nuclear in tissue (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A02550-1). Validated IHC antibody: A02550-1 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human gastric cancer tissue; fixative not specified (datasheet A02550-1); 2. Fixation: Image fixative and duration unreported (datasheet A02550-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A02550-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A02550-1); 8. Primary antibody: Rabbit anti-DHX9, 0.5-1μg/ml (datasheet A02550-1); 9. Primary incubation: Overnight at 4 °C (datasheet A02550-1). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Nucleocytoplasmic shuttling may add cytoplasmic signal (UniProt); Isoform / epitope: 2 isoforms; antibody epitope coverage is unknown (UniProt); Regulation: Low tissue specificity (HPA tissue RNA). Evidence: UniProt Q08211, HPA tissue IHC · Supported, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet A02550-1, PMC11816161, PMC8649379. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/DHX9/immunohistochemistry-ihc-guide.